by kati.sallinen@desentum.fi | Dec 2, 2025 | News
Desentum, a clinical-stage biotechnology company developing novel allergen immunotherapies, announced today that the first trial participants have received their first doses in a Phase 2 clinical study, BASIT, evaluating DM-101PX for treatment of birch pollen allergy....
by kati.sallinen@desentum.fi | Aug 27, 2025 | News
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a Phase 2 clinical study with DM-101PX, an investigational immunotherapeutic treatment for birch pollen allergy. Approximately 100 birch pollen allergic adults will...
by kati.sallinen@desentum.fi | Jun 3, 2025 | News
Desentum Oy:n osakkeenomistajat kutsutaan yhtiön varsinaiseen yhtiökokoukseen, joka pidetään 23.6.2025 klo 10.00 alkaen osoitteessa Technopolis, Innopoli 2, Tekniikantie 14, 02150 Espoo. Kokoushuone: Edison 2. Yhtiökokousta voi seurata Teams-etäyhteyden...
by kati.sallinen@desentum.fi | May 16, 2025 | News
All three abstracts submitted by Desentum have been accepted for oral presentations at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Glasgow, UK, on Jun 13–16, 2025. Two of the presentations will showcase the...
by kati.sallinen@desentum.fi | Apr 2, 2025 | News
Desentum Oy, a clinical-stage biopharmaceutical company developing novel immunotherapies for treating allergies, announces positive clinical data with birch pollen allergy vaccine DM-101PX. The short-course treatment was found to be safe and well tolerated in birch...
by kati.sallinen@desentum.fi | Jan 31, 2025 | News
Desentum Oy:n (“Yhtiö”) yhtiöjärjestyksen 9 §:n mukaisesti osakkeenomistajille ilmoitetaan, että Exu Capital Oy on myynyt yhteensä 6000 B-osaketta (“Osakkeet”) 2,00 euron osakekohtaiseen hintaan. Osakkeiden siirtymisestä on...
